Minimus Spine™ Receives Notice of Allowance for its Syringe Designed to Produce Ozone for Spinal Injection.

Minimus Spine, Inc. (www.minimusspine.com) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (Application 11/976,362). “This patent protects our sterile, disposable syringe, which interfaces with a desktop unit to produce and measure ozone at the patient’s bedside,” said David Hooper, Ph.D. Minimus Spine’s Founder and CEO. “The syringe will give the physician and patient confidence that the injection is done in a sterile manner. This is a significant addition to Minimus Spine’s growing portfolio of intellectual property and builds upon previous patents already issued in the U.S. and Asia. This Notice of Allowance, coupled with the existing body of peer-reviewed literature, supports our continued effort to commercialize this product. We are progressing towards clinical trials and have identified a number of potential sites overseas. If the product can be successfully commercialized, it would enable many patients to avoid repeated spinal injections and surgery, reducing the cost of care considerably.”

About Minimus Spine: Established in 2006, Minimus Spine is a privately held medical device company dedicated to developing ozone technology for medical applications. The company is focused on the treatment of spinal disorders related to herniated discs. Minimus Spine is headquartered in Austin, TX. For more information on Minimus Spine, please visit http://www.minimusspine.com.